{"id":25246,"date":"2025-09-10T10:25:35","date_gmt":"2025-09-10T14:25:35","guid":{"rendered":"https:\/\/www.insightpartners.com\/?p=25246"},"modified":"2025-09-10T10:25:35","modified_gmt":"2025-09-10T14:25:35","slug":"optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond","status":"publish","type":"post","link":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/","title":{"rendered":"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond"},"content":{"rendered":"

Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain’s advanced robotic retinal imaging, AI, and teleophthalmology platform.<\/b><\/p>\n

NEW YORK<\/span><\/span>,\u00a0Sept. 10, 2025<\/span><\/span>\u00a0\/PRNewswire\/ —\u00a0Optain Health,\u00a0<\/b>a healthcare technology company applying artificial intelligence (AI), robotic retinal imaging, and teleophthalmology to detect eye and systemic disease earlier, today announced the close of an oversubscribed\u00a0$26 million<\/span>\u00a0Series A. The raise was led by global software investor Insight Partners with participation from existing investors.<\/p>\n

A single, non-invasive test, run anywhere:\u00a0<\/b>Oculomics\u2014the science of using the eye as a window into whole-body health\u2014powers Optain’s platform. Its portable robotic camera captures retinal images rapidly without requiring pupil dilation. Integrated AI workflows detect sight-threatening eye diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration, and assess cardiovascular disease risk. In the U.S., Optain delivers rapid teleophthalmology grading to screen for diabetic retinopathy and more. Optain’s technology expands access to oculomics into primary care, optometry, and beyond, with minimal specialist staffing or workflow disruption.<\/p>\n

“Our mission is simple: faster, easier, more equitable disease screening,” said\u00a0Jeff Dunkel<\/span>, CEO, Optain. “After two years of major international growth, we are ready to scale in the U.S. This Series A funds our enterprise deployments, opens new markets, and pushes the frontier of what the retina can reveal.”<\/p>\n

Strategic health system and global investor participation:\u00a0<\/b>Insight was joined by seven leading health system investors, among them: Memorial Hermann Health System, Northwell Health, Novant Health, The\u00a0Ohio State University<\/span>\u00a0Wexner Medical Center, and UPMC. Together, these systems deliver care to 28 million patients across 25 states. Each will begin deploying Optain’s platform across their networks to expand screening access, close care gaps, and improve outcomes. Additional investors, including Informed Ventures, Lumio Capital, Meridian Ventures, and the UniQuest Extension Fund will accelerate the growth of Optain’s global footprint in\u00a0Australia<\/span>,\u00a0Europe<\/span>, the\u00a0Middle East<\/span>, and\u00a0Southeast Asia<\/span>.<\/p>\n

“Optain represents our conviction in the power of better AI\u2014deployed at the edge, inside clinical workflows,” said\u00a0Scott Barclay<\/span>, Managing Director at Insight Partners. “By making retinopathy screening truly accessible,\u00a0Optain is already changing care delivery\u2014and we believe it will become the upstream gateway in primary care for AI-driven diagnoses across many conditions.”<\/p>\n

Backed by leading health systems and clinical leaders.<\/b>\u00a0Optain was co-created in 2023 by Aegis Ventures which also formed the Aegis Digital Consortium, a collaboration of 11 leading regional U.S. health systems to co-develop AI-driven healthtech companies. “Early retinal screening for diabetic retinopathy and chronic disease closes a critical care gap,” said Dr.\u00a0John Noseworthy<\/span>, Chairman of the Aegis Digital Consortium and Emeritus CEO of Mayo Clinic. “Clinicians have been waiting for a solution that meets patients where they are, and Optain is delivering a best-in-class product that is achieving real adoption. By deploying Optain in patient care and investing in the company, Consortium members have shown strong confidence in its value for enabling early detection and better outcomes.” Dr. Noseworthy will join Optain’s board as an observer, representing the strategic health systems.<\/p>\n

Australian R&D powering global impact.<\/b>\u00a0Optain’s technology builds on more than a decade of research led by Professor\u00a0Mingguang He<\/span>\u00a0in\u00a0Australia<\/span>. “We’re proud to be translating world-class Australian science into real-world impact,” said Dr.\u00a0Zachary Tan<\/span>, President of Optain. “We are making significant investments in new Australian R&D and growing our local team, who will lead our global expansion outside of the U.S. Exporting Australian AI innovation to improve equitable access to healthcare and patient outcomes around the world is a mission we are proud to lead.”<\/p>\n

About\u00a0Optain
<\/b>Optain transforms preventive health with AI-enabled software and hardware that deliver real-time, non-invasive detection of eye and systemic conditions. Its portable robotic retinal camera, AI, and teleophthalmology service give clinicians an affordable point-of-care tool to close care gaps, reduce avoidable costs, and improve patient outcomes. Learn more at\u00a0optainhealth.com\/us<\/a><\/u>\u00a0and follow us on\u00a0LinkedIn<\/a><\/u>.<\/p>\n

About Insight Partners
<\/b>Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of\u00a0December 31, 2024<\/span>, the firm has over\u00a0$90B<\/span>\u00a0in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in\u00a0New York City<\/span>, Insight has offices in\u00a0London<\/span>,\u00a0Tel Aviv<\/span>, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.<\/p>\n","protected":false},"excerpt":{"rendered":"

Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain’s advanced robotic retinal imaging, AI, and teleophthalmology platform. NEW YORK,\u00a0Sept. 10, 2025\u00a0\/PRNewswire\/ —\u00a0Optain Health,\u00a0a healthcare technology company applying artificial intelligence (AI), robotic retinal imaging, and teleophthalmology to detect eye and systemic disease earlier, today announced the close of an […]<\/p>\n","protected":false},"author":27,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-25246","post","type-post","status-publish","format-standard","hentry","category-uncategorized","idea_types-news"],"acf":[],"yoast_head":"\nOptain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond | Insight Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond\" \/>\n<meta property=\"og:description\" content=\"Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain’s advanced robotic retinal imaging, AI, and teleophthalmology platform. NEW YORK,\u00a0Sept. 10, 2025\u00a0\/PRNewswire\/ —\u00a0Optain Health,\u00a0a healthcare technology company applying artificial intelligence (AI), robotic retinal imaging, and teleophthalmology to detect eye and systemic disease earlier, today announced the close of an […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/\" \/>\n<meta property=\"og:site_name\" content=\"Insight Partners\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-10T14:25:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.insightpartners.com\/wp-content\/uploads\/2023\/01\/Inisghtpartners.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1255\" \/>\n\t<meta property=\"og:image:height\" content=\"650\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Kristen Zeck\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@insightpartners\" \/>\n<meta name=\"twitter:site\" content=\"@insightpartners\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kristen Zeck\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/\"},\"author\":{\"name\":\"Kristen Zeck\",\"@id\":\"https:\/\/www.insightpartners.com\/#\/schema\/person\/67970b1996c569d0aa3f6f01d8151733\"},\"headline\":\"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond\",\"datePublished\":\"2025-09-10T14:25:35+00:00\",\"dateModified\":\"2025-09-10T14:25:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/\"},\"wordCount\":796,\"publisher\":{\"@id\":\"https:\/\/www.insightpartners.com\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/\",\"url\":\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/\",\"name\":\"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond | Insight Partners\",\"isPartOf\":{\"@id\":\"https:\/\/www.insightpartners.com\/#website\"},\"datePublished\":\"2025-09-10T14:25:35+00:00\",\"dateModified\":\"2025-09-10T14:25:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.insightpartners.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.insightpartners.com\/#website\",\"url\":\"https:\/\/www.insightpartners.com\/\",\"name\":\"Insight Partners\",\"description\":\"Scaling the Future of AI\",\"publisher\":{\"@id\":\"https:\/\/www.insightpartners.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.insightpartners.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.insightpartners.com\/#organization\",\"name\":\"Insight Partners\",\"url\":\"https:\/\/www.insightpartners.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.insightpartners.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/insightpartners.com\/wp-content\/uploads\/2023\/01\/Inisghtpartners.png\",\"contentUrl\":\"https:\/\/insightpartners.com\/wp-content\/uploads\/2023\/01\/Inisghtpartners.png\",\"width\":1255,\"height\":650,\"caption\":\"Insight Partners\"},\"image\":{\"@id\":\"https:\/\/www.insightpartners.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/insightpartners\",\"https:\/\/www.linkedin.com\/company\/insight--partners\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.insightpartners.com\/#\/schema\/person\/67970b1996c569d0aa3f6f01d8151733\",\"name\":\"Kristen Zeck\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.insightpartners.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fb95e3f0e5d68b470c98e51f80796a62?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fb95e3f0e5d68b470c98e51f80796a62?s=96&d=mm&r=g\",\"caption\":\"Kristen Zeck\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond | Insight Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/","og_locale":"en_US","og_type":"article","og_title":"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond","og_description":"Insight Partners leads; seven major U.S. health systems join. Funding accelerates the global rollout of Optain’s advanced robotic retinal imaging, AI, and teleophthalmology platform. NEW YORK,\u00a0Sept. 10, 2025\u00a0\/PRNewswire\/ —\u00a0Optain Health,\u00a0a healthcare technology company applying artificial intelligence (AI), robotic retinal imaging, and teleophthalmology to detect eye and systemic disease earlier, today announced the close of an […]","og_url":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/","og_site_name":"Insight Partners","article_published_time":"2025-09-10T14:25:35+00:00","og_image":[{"width":1255,"height":650,"url":"https:\/\/www.insightpartners.com\/wp-content\/uploads\/2023\/01\/Inisghtpartners.png","type":"image\/png"}],"author":"Kristen Zeck","twitter_card":"summary_large_image","twitter_creator":"@insightpartners","twitter_site":"@insightpartners","twitter_misc":{"Written by":"Kristen Zeck","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/#article","isPartOf":{"@id":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/"},"author":{"name":"Kristen Zeck","@id":"https:\/\/www.insightpartners.com\/#\/schema\/person\/67970b1996c569d0aa3f6f01d8151733"},"headline":"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond","datePublished":"2025-09-10T14:25:35+00:00","dateModified":"2025-09-10T14:25:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/"},"wordCount":796,"publisher":{"@id":"https:\/\/www.insightpartners.com\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/","url":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/","name":"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond | Insight Partners","isPartOf":{"@id":"https:\/\/www.insightpartners.com\/#website"},"datePublished":"2025-09-10T14:25:35+00:00","dateModified":"2025-09-10T14:25:35+00:00","breadcrumb":{"@id":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.insightpartners.com\/ideas\/optain-health-closes-26-million-series-a-to-bring-oculomics-to-primary-care-and-beyond\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.insightpartners.com\/"},{"@type":"ListItem","position":2,"name":"Optain Health Closes $26 Million Series A to Bring Oculomics to Primary Care and Beyond"}]},{"@type":"WebSite","@id":"https:\/\/www.insightpartners.com\/#website","url":"https:\/\/www.insightpartners.com\/","name":"Insight Partners","description":"Scaling the Future of AI","publisher":{"@id":"https:\/\/www.insightpartners.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.insightpartners.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.insightpartners.com\/#organization","name":"Insight Partners","url":"https:\/\/www.insightpartners.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.insightpartners.com\/#\/schema\/logo\/image\/","url":"https:\/\/insightpartners.com\/wp-content\/uploads\/2023\/01\/Inisghtpartners.png","contentUrl":"https:\/\/insightpartners.com\/wp-content\/uploads\/2023\/01\/Inisghtpartners.png","width":1255,"height":650,"caption":"Insight Partners"},"image":{"@id":"https:\/\/www.insightpartners.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/insightpartners","https:\/\/www.linkedin.com\/company\/insight--partners"]},{"@type":"Person","@id":"https:\/\/www.insightpartners.com\/#\/schema\/person\/67970b1996c569d0aa3f6f01d8151733","name":"Kristen Zeck","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.insightpartners.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fb95e3f0e5d68b470c98e51f80796a62?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fb95e3f0e5d68b470c98e51f80796a62?s=96&d=mm&r=g","caption":"Kristen Zeck"}}]}},"_links":{"self":[{"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/posts\/25246"}],"collection":[{"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/users\/27"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/comments?post=25246"}],"version-history":[{"count":2,"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/posts\/25246\/revisions"}],"predecessor-version":[{"id":25250,"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/posts\/25246\/revisions\/25250"}],"wp:attachment":[{"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/media?parent=25246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/categories?post=25246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insightpartners.com\/wp-json\/wp\/v2\/tags?post=25246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}